- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Cost-Sharing Roundtable—Introduction
Healthcare cost-sharing remains a significant barrier to healthcare access, especially among patients with chronic conditions or those with financial constraints, and could prevent patients from getting much-needed health services, use of diagnostic tests, or result in adherence issues due to patients skipping doses or not filling their prescription medications. At the Cost-Sharing Roundtable on February 23, 2018, presenters and panelists—from academic institutions, health policy organizations, and charitable foundations—shared their findings and experiences with financial hardships faced by patients, and brain stormed ideas on how best to address the situation via practical advice and policy changes.
Healthcare cost-sharing remains a significant barrier to healthcare access, especially among patients with chronic conditions or those with financial constraints, and could prevent patients from getting much-needed health services, use of diagnostic tests, or result in adherence issues due to patients skipping doses or not filling their prescription medications.
At the Cost-Sharing Roundtable on February 23, 2018, presenters and panelists—from academic institutions, health policy organizations, and charitable foundations—shared their findings and experiences with financial hardships faced by patients, and brain stormed ideas on how best to address the situation via practical advice and policy changes.
Speakers:
Amy Niles, vice president of external relations of the Patient Access Network (PAN) Foundation
Surabhi Dangi-Garimella, PhD, associate editorial director, The American Journal of Managed Care®
Dan Klein, president and CEO of the PAN Foundation.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity
July 1st 2025Joshua K. Sabari, MD, of NYU Langone Health discusses promising results for zongertinib in HER2-mutant NSCLC; the tyrosine kinase inhibitor offers high response rates and improved quality of life with minimal toxicity.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
